References
- Collett B J. Opioid tolerance: The clinical perspective. Br J Anaesth 1998; 81: 58–68
- Pasternak G W. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacology Sci 2001; 22: 67–70
- Pasternak G W. The pharmacology of mu analgesics: From patients to genes. Neuroscientist 2001; 7: 220–231
- Crews J C, Sweeney N J, Denson D D. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer 1993; 72: 2266–2272
- Manfredi P L, Borsook D, Chandler S W, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations. Pain 1997; 70: 99–101
- Fitzgibbon D R, Ready L B. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 1997; 73: 259–261
- Sabatowski R, Kasper S M, Radbruch L. Patient-controlled analgesia with intravenous L-methadone in a child with cancer pain refractory to high-dose morphine. J Pain Symptom Manage 2002; 23: 3–5
- Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997; 70: 109–115
- Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin North Am 2002; 16: 543–555
- Mercadante S. Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer 1999; 86: 1856–1866
- Indelicato R A, Portenoy R K. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002; 20: 348–352
- Bulka A, Plesan A, Xu X J, Wiesenfeld-Hallin Z. Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy. Pain 2002; 95: 103–109
- Doverty M, Somogyi A A, White J M, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 2001; 93: 155–163
- Arcuri E, Ginobbi P, Tirelli W, Froldi R, Citro G, Santoni A. Preliminary in vivo experimental evidence on intratumoral morphine uptake. Possible clinical implications in cancer pain and opioid responsiveness. J Pain Symptom Manage 2002; 24: 1–3
- Woolf C J. Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Research 1981; 209: 491–495
- Morley J S, Watt J W, Wells J C, Miles J B, Finnegan M J, Leng G. Methadone in pain uncontrolled by morphine. Lancet 1993; 342: 1243
- Rapp S E, Ready L B, Nessly M L. Acute pain management in patients with prior opioid consumption: A case-controlled retrospective review. Pain 1995; 61: 195–201
- Coyle N, Adelhardt J, Foley K M, Portenoy R K. Character of terminal illness in the advanced cancer patient: Pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990; 5: 83–93
- Hashimoto Y, Takarada M, Tanioka H, Rigor B M. Treatment of cancer pain of the head and neck by continuous intravenous infusion of high-dose morphine: Report of two cases. J Oral Maxillofac Surg 1990; 48: 398–400
- Radbruch L, Grond S, Zech D J, Bischoff A. High-dose oral morphine in cancer pain management: A report of twelve cases. J Clin Anesth 1996; 8: 144–150
- Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids: A critical review and proposals for long-term dosing. J Pain Symptom Manage 2001; 22: 672–687
- Moryl N, Santiago-Palma J, Kornick C, et al. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain 2002; 96: 325–328